Abstract
Obesity has been described as a ' public health time-bomb' . In 2005, the World
Health Organization estimated that approximately 400 million individuals are
obese. Prevalence of obesity is rising worryingly in many countries, despite
campaigns emphasizing the link between being overweight and contracting
diabetes. This new report - Anti-Obesity Treatments 2009-2024 - explains
those trends in commercial terms. In two of the largest national markets for
anti-obesity treatments - the US and UK - over 20% of the population are
seriously overweight. Obesity is a major risk factor in a number of other
serious disorders, particularly diabetes and heart disease. Importantly, the
financial burden of obesity and its associated conditions - both direct and
indirect costs - are vast. Obesity is a serious, chronic condition with an
emerging market for therapeutic products, as we show in this study. High
socioeconomic costs and increasing prevalence are inspiring government
initiatives to deal with the problem, with obesity becoming one of the most
prominent global health concerns worldwide. Visiongain recognizes the
contribution of drugs in this important emerging market, as diet and exercise
are frequently not successful alone. We predict that new classes of drugs will
invigorate the market - driving total sales in the next decade. In this report
you will find out about those treatments, especially their sales potential.
Drug sales in the global anti-obesity market approached $2bn in 2008, with the
market to grow substantially over the forecast period 2009-2024. This growth
will be associated with a complex environment of label changes,
reformulations, patent expiry, OTC switching and new product launches. Those
opportunities are highlighted by the extensive R&D pipeline, crowded with
novel therapies to improve treatment of obesity. Which new treatments have
blockbuster potential? Our report will cover this and other important matters.
Importantly, too, prevalence of obesity is rising in Latin America, India and
China in particular - important pharmaceutical markets covered here.
Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global
anti-obesity market, with comprehensive sales forecasting. With a rigorous
study of sources, including commercial databases, company reports, industry
news and first-hand interviews with experts in the obesity sector, this report
is a unique opportunity to discover how your company can develop over the next
5 years. The result is a comprehensive market- and industry-based report with
detailed analyses and informed opinion that you will not find anywhere else.
Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market:
- A global forecast for the anti-obesity drugs market with comprehensive
discussions
- Sales forecasts for the current-leading drugs
- Assessment of new drug releases, both therapeutically and commercially
- Sales forecasts for the leading national anti-obesity markets, as well as
for emerging national markets
- Discussion of strengths, weakness, opportunities and threats (SWOT) facing
major stakeholders in the anti-obesity drug sector
- Extensive analysis of pipeline developments, including avenues for future
research
- Discussion of current un-met and under-met needs in the anti-obesity
market, revealing both therapeutic needs and commercial opportunities.
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for anti-obesity
therapies from 2009-2024, including predicted revenues, growth rates and other
key metrics
- To identify key pipeline developments, the most promising therapy classes
and potential methods of treatment
- To discover the important drivers and restraints for the global
anti-obesity market, including factors affecting leading national markets
- To find out where the global anti-obesity market is heading - both
technologically and commercially - from the present onwards.
This report is essential reading for anyone in the pharmaceutical and
healthcare sector with an interest in obesity and related conditions.
Purchasing this report will help you to recognise those important market
opportunities and understand the possibilities there.
| 
View Cart
